Transforming Disease Monitoring

Transforming disease monitoring and treatment response

Our Vision

Imagine a future where disease is intercepted earlier, better therapies are developed faster, people don’t become patients and patients are returned to health. At Glympse Bio, we are working to turn this future into a reality. Take a glimpse into that future, where we are taking a glimpse inside the body.


What We Do


A Simple Question

In many of today’s most common and serious diseases few biomarkers (biological markers of disease) have been identified that can effectively and reliably detect disease or track response to treatment. At Glympse, we asked ourselves a simple question: why not directly query disease activity instead? From this simple question we have built a disruptive, non-invasive technology to directly query disease activity inside the body. We’re now on a journey with our platform to transform disease detection, predict treatment responders, measure treatment response, and track patients back to health.

Synthetic biomarkers: Perfectly Tunable

We are pioneering the development of synthetic biomarkers – biological sensors developed using breakthroughs in science, engineering, medicine and artificial intelligence – that are bioengineered to be perfectly tunable to any disease, absolutely specific, and offer earlier measures of response to disease and treatment.


Liquid Biopsy: Query the Body, Not a Sample

Our synthetic biomarkers are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. Synthetic biomarkers exploit the human body’s own proteases and in vivo trafficking to create perfectly refined and trackable markers of disease which are accurate, sensitive, specific and detectable in a simple noninvasive urine test. It’s the new frontier of liquid biopsy.

Biology-AI Convergence: Glympse Inside™

We are building a comprehensive database of real-time biological activity in the human body that drives insights to validate drug-target engagement, determine responders and non-responders, and drive earlier and stronger outcomes for patients. At the earliest stages, we can gain a glimpse into the stage and progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections.

At the core of our product engine is the integration of sophisticated machine learning and artificial intelligence to develop predictive algorithms targeting all clinically-relevant proteases involved in human biology and physiology. All trained by our unique approach that captures real-time biology inside the body – Glympse Inside™.


Deep Pipeline: Large Markets, High Unmet Need

Our lead program is Non-Alcoholic Steatohepatitis (NASH), impacting 16 million people in the U.S. and 100 million worldwide. We are developing predictive biomarkers that allow us to noninvasively and accurately stage NASH with a liquid biopsy better than the current standard of invasive needle liver biopsy. The same liquid biopsy reliably measures response to therapy long before histopathology changes become visible.

Our next program is Oncology, impacting 14 million patients in the U.S. and 50 million worldwide. We are developing a synthetic biomarker-based liquid biopsy to directly track progression of specific cancers and response to treatment longitudinally, across a broad range of immunotherapies, targeted therapies, and other standards-of-care.

Our development pipeline features programs in Oncology and Infections with preclinical validation in 10+ additional diseases.

Disruptive Business Model

Our creative business model uniquely blends the best of a drug-device development and regulatory pathway, therapeutics go-to-market model, and a biology-rich data engine.


Who We Are

Founded in 2015, Glympse Bio is an MIT spin-out from the laboratory of renowned bioengineer, Dr. Sangeeta Bhatia. Glympse Bio is headquartered in Cambridge, MA.

Our team is committed to enhancing our understanding of human disease. Our goal is to better serve the needs of patients, clinicians, researchers, drug developers, and payors.


Our Values

Deliver Scientific Excellence

Our dedication to science, across all the disciplines we integrate, is fundamental. This focus drives us together to our most exciting discoveries. And we always deliver.

Push Boundaries

Disruption was never achieved by accepting the status quo. Every day we challenge what has been accepted as we aspire to deliver a better future.

Show Courage

We all act with courage as we strive to achieve our vision. We will not fear failure. We will celebrate and learn equally from our failures and successes.

Always Collaborate

Every role matters in our team. We collaborate to ensure our common objectives are achieved.

Act with Integrity

This is who we are. And we are unwavering in our commitment to act with the highest ethics and integrity, to each other and those we work with.


Our Team



Board of Directors


Scientific Advisors

Carolyn Bertozzi, Ph.D.
Bass Professor of Chemistry, Stanford

Charles S. Craik, Ph.D.
Professor of Pharmaceutical Chemistry, UCSF

Clinical Advisors

Scott Friedman, M.D.
Chief, Division of Liver Diseases, Icahn School of Medicine, Mt. Sinai 

Rohit Loomba, M.D., MHSc.
Director of Hepatology; Vice Chief, Division of Gastroenterology, UCSD

Arun Sanyal, M.D.
Professor, Division of Gastroenterology, Hepatology & Nutrition, VCU 

Gyongzi Szabo, M.D., Ph.D., FAASLD
Chief Academic Officer, Beth Israel Deaconess Medical Center




Join Us

We are a dynamic and high energy team that is committed to pushing scientific boundaries in pursuit of our goals. We are creative, agile, resilient, and always have the ‘courage to continue’. We work as a team, committed to each other’s success, in an environment where every team member is important.

If you fit the Glympse Bio profile, we would love to talk to you! We are actively building our team and welcome talented individuals who are looking to make a lasting impact.



Glympse Bio has a proven, flexible and customizable technology platform – powered by a highly scalable product engine – that can be deployed in multiple markets and applications. Best of all, our platform comes packaged in a favorable device regulatory pathway and drug reimbursement model.

We are excellent collaborators who consistently deliver for partners that share our vision and passion for changing the way treatments are developed, healthcare is delivered, and patients are diagnosed, treated, and monitored. Together, we can do this and enhance value for our partners and ourselves.

Group image - 2 copy.jpg


We are looking for distinctive people to join our fabulous team. And we are growing rapidly!